Indication

FGFR2 Gene Rearrangement

1 clinical trial

1 product

Clinical trial

A Phase II Study of Pemigatinib After Curative Local Therapy in Locally Advanced Intrahepatic Cholangiocarcinoma (iCCA) Harboring FGFR2 Fusions/Rearrangements.

Status: Recruiting, Estimated PCD: 2025-11-01

Product